SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indrayani Biotech surges as its arm acquires 51% stake in HIPL

08 Dec 2022 Evaluate

Indrayani Biotech is currently trading at Rs. 95.85, up by 4.55 points or 4.98% from its previous closing of Rs. 91.30 on the BSE.

The scrip opened at Rs. 93.70 and has touched a high and low of Rs. 95.85 and Rs. 93.70 respectively. So far 37408 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 115.70 on 23-Sep-2022 and a 52 week low of Rs. 18.40 on 03-Mar-2022.

Last one week high and low of the scrip stood at Rs. 95.85 and Rs. 89.60 respectively. The current market cap of the company is Rs. 328.07 crore.

The promoters holding in the company stood at 44.89%, while Institutions and Non-Institutions held 19.17% and 35.94% respectively.

 Indrayani Biotech’s wholly owned subsidiary -- IBL Healthcare has acquired 5,10,000 equity shares, constituting 51% of total no of equity shares, of Healthway India (HIPL). Thus, HIPL has become a subsidiary company of IBL Healthcare. The cost of acquisition is Rs 5.10 lakh.

Indrayani Biotech is a company belonging to food sector. They are a part-finance its project to produce cut flowers, strawberries, tissue culture plantlets and hybrid vegetable seeds. The company also markets and distributes hybrid vegetable seeds manufactured by Hoechst India. It plans to produce these seeds for Hoechst in due course of time.

Indrayani Biotech Share Price

12.08 -0.06 (-0.49%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Grasim Industries 2757.45
DCM Shriram 1198.95
3M India 31427.05
Hindustan Foods 494.80
Balmer Lawrie & Co 177.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×